Universal Beteiligungs und Servicegesellschaft mbH Has $3.90 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 22.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,528 shares of the company’s stock after purchasing an additional 11,637 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.13% of Prestige Consumer Healthcare worth $3,902,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new position in Prestige Consumer Healthcare during the third quarter valued at approximately $1,890,000. AXQ Capital LP bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth $694,000. Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the last quarter. Tributary Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 157.3% in the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock worth $23,675,000 after acquiring an additional 231,969 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Prestige Consumer Healthcare by 13.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,571 shares of the company’s stock valued at $765,000 after acquiring an additional 1,134 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $64.03 on Wednesday. The company has a 50 day moving average of $62.23 and a 200-day moving average of $64.49. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 2.06 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The firm had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group lowered their target price on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Oppenheimer cut their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $85.33.

Insider Activity

In other news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.40% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).